Google
ESLAW 株価分析 — Estrella Immunopharma Inc. (Healthcare >> Biotechnology)
ESLAW に関するよくある質問
ESLAWのROE（自己資本利益率）は？
Estrella Immunopharma Inc.のROEは251.43%です。
ESLAWの配当利回りは？
Estrella Immunopharma Inc.の配当利回りは0.00%です。
ESLAWの品質スコア（Quality Score）は？
当社のAIはESLAWの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ESLAWは今が買い時ですか？
当社AIのタイミングスコアは100点中2点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ESLAWはどのセクターに属しますか？
Estrella Immunopharma Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ESLAW AI Analysis Summary
Our AI summary for ESLAW: Estrella Immunopharma Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 251.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 2/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.07
Price
0.01
(9.24%)
Day Change
|
|
|---|
ESLAW, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 87 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.07 |
| PBV / Sector |
N/A / 44,105.10
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
553.228110000000
|
| Average 1W Daily Value |
124.307880000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:57 |
| Symbol | ESLAW |
| Name | ESTRELLA IMMUNOPHARMA INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.00 |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 5858 Horton Street, EmeryVille, CA, United States, 94608
Phone: 510 318 9098
Website: https://www.estrellabio.com
Sector: Healthcare >> Biotechnology
Description: Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
